News
OCSAW
5.12
+8.25%
0.39
Weekly Report: what happened at OCSAW last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at OCSAW last week (1125-1129)?
Weekly Report · 12/02 09:58
Weekly Report: what happened at OCSAW last week (1118-1122)?
Weekly Report · 11/25 09:54
Weekly Report: what happened at OCSAW last week (1111-1115)?
Weekly Report · 11/18 09:53
Weekly Report: what happened at OCSAW last week (1104-1108)?
Weekly Report · 11/11 09:58
Weekly Report: what happened at OCSAW last week (1028-1101)?
Weekly Report · 11/04 09:58
Weekly Report: what happened at OCSAW last week (1021-1025)?
Weekly Report · 10/28 09:54
Weekly Report: what happened at OCSAW last week (1014-1018)?
Weekly Report · 10/21 09:53
Weekly Report: what happened at OCSAW last week (1007-1011)?
Weekly Report · 10/14 10:04
Weekly Report: what happened at OCSAW last week (0930-1004)?
Weekly Report · 10/07 10:00
Weekly Report: what happened at OCSAW last week (0923-0927)?
Weekly Report · 09/30 09:57
Weekly Report: what happened at OCSAW last week (0916-0920)?
Weekly Report · 09/23 09:57
Weekly Report: what happened at OCSAW last week (0909-0913)?
Weekly Report · 09/16 09:53
Weekly Report: what happened at OCSAW last week (0902-0906)?
Weekly Report · 09/09 09:57
Weekly Report: what happened at OCSAW last week (0826-0830)?
Weekly Report · 09/02 09:58
Weekly Report: what happened at OCSAW last week (0819-0823)?
Weekly Report · 08/26 09:57
Weekly Report: what happened at OCSAW last week (0812-0816)?
Weekly Report · 08/19 09:52
Weekly Report: what happened at OCSAW last week (0805-0809)?
Weekly Report · 08/12 09:53
Weekly Report: what happened at OCSAW last week (0729-0802)?
Weekly Report · 08/05 09:57
Weekly Report: what happened at OCSAW last week (0722-0726)?
Weekly Report · 07/29 09:54
More
Webull provides a variety of real-time OCSAW stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCSAW
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.